EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report

Ryo Takada, Miki Fujiwara, Masatoshi Maki, Naoyuki Nomura, Shintaro Kono, Akira Fujita, Hiroshi Masumoto, Yoko Takahashi, Yasuhisa Hasegawa, Koji Tamura

Journal of Pharmaceutical Health Care and Sciences · 31.05.2024 · 10 (1)

DOI: 10.1186/s40780-024-00348-8 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Pharmaceutical Health Care and Sciences, online erschienen am 31.05.2024. Verfasst von Ryo Takada und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmacy, National Hospital Organization Fukuyama Medical Center, 4-14-17 Okinogami-cho, Fukuyama City, Hiroshima, 720-8520, J…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ipilimumab (Ipi) plus nivolumab (Nivo) is the recommended first-line treatment for renal cell carcinoma (RCC). This report describes a case where pancreatic metastases disappeared after only two courses of Ipi + Nivo therapy. The primary tumor was cured by surgery, and a pathological Complete Response (pCR) was observed despite multiple serious immune-related Adverse Events (irAEs). Case presentation A 54-year-old woman with RCC and pancreatic metastasis at stage IV, diagnosed with intermediate risk according to the International Metastatic RCC Database Consortium classification, underwent initiation of Ipi + Nivo therapy. On day 26, she developed hyperthyroidism accompanied by tachycardia, leading to the commencement of metoprolol tartrate treatment. Following the resolution of tachycardia, a second course of Ipi + Nivo therapy was administered on day 50. By day 70, the patient exhibited Grade 3 hepatic dysfunction, followed by the onset of hypothyroidism on day 75, necessitating treatment with steroids and levothyroxine. After positive treatment, a Grade 3 skin disorder emerged on day 87 while tapering steroids, prompting treatment with methylprednisolone (mPSL) pulse therapy. The skin disorder responded to steroids, allowing for tapering. However, on day 113, a recurrence of Grade 3 skin disorder occurred, necessitating another mPSL pulse. The patient responded well to treatment, exhibiting improvement in her condition. On day 131, she presented at the hospital with complaints of respiratory distress, prompting a Computed Tomography (CT) scan that revealed interstitial pneumonia. By day 272, subsequent CT imaging showed the disappearance of pancreatic metastasis and shrinkage of the primary tumor. On day 294, she underwent a laparoscopic left nephrectomy. Pathological analysis confirmed a pCR in the primary tumor, indicating successful eradication of RCC through surgical intervention.

Conclusions

This case report presents a scenario where multiple severe irAEs appeared in a patient, yet metastases disappeared after only two courses of Ipi + Nivo therapy. The patient was ultimately cured by surgery and achieved a pCR. This case highlights that despite the occurrence of severe irAEs during RCC treatment with Ipi + Nivo therapy, they can be managed appropriately to maximize the therapeutic effects of checkpoint inhibitors.

Schlagwörter

Stichwörter der Autor:innen

Immune checkpoint inhibitorsIpilimumabNivolumabRenal cell carcinomairAEs

Autor:innen und Institutionen

  • Department of Hospital Pharmacy, National Hospital Organization Fukuyama Medical Center, 4-14-17 Okinogami-cho, Fukuyama City, Hiroshima, 720-8520, Japan. takada.ryo.nw@mail.hosp.go.jp.
  • Department of Hospital Pharmacy, National Hospital Organization Fukuyama Medical Center, 4-14-17 Okinogami-cho, Fukuyama City, Hiroshima, 720-8520, Japan.
  • Department of Urology, National Hospital Organization Fukuyama Medical Center, Fukuyama, Japan.

Zitieren

APA

Takada, R., Fujiwara, M., Maki, M., Nomura, N., Kono, S., Fujita, A., Masumoto, H., Takahashi, Y., Hasegawa, Y., & Tamura, K. (2024). Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report. Journal of Pharmaceutical Health Care and Sciences, 10(1). https://doi.org/10.1186/s40780-024-00348-8

Vancouver

Takada R, Fujiwara M, Maki M, Nomura N, Kono S, Fujita A, et al. Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report. Journal of Pharmaceutical Health Care and Sciences. 2024;10(1). doi:10.1186/s40780-024-00348-8

BibTeX
@article{Takada2024,
  author = {Takada, Ryo and Fujiwara, Miki and Maki, Masatoshi and Nomura, Naoyuki and Kono, Shintaro and Fujita, Akira and Masumoto, Hiroshi and Takahashi, Yoko and Hasegawa, Yasuhisa and Tamura, Koji},
  title = {Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report},
  journal = {Journal of Pharmaceutical Health Care and Sciences},
  year = {2024},
  volume = {10},
  number = {1},
  doi = {10.1186/s40780-024-00348-8}
}
Kostenlos starten →